|Articles|March 11, 2021
- Pharmaceutical Executive-03-01-2021
- Volume 41
- Issue 3
Pharmaceutical Executive, March 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 5 years ago
The Amazon Effect: A Data-Fueled Customer Experienceabout 5 years ago
Why ESG Performance Metrics Matterabout 5 years ago
Pharma and Biotech’s 2020 Full-Year Viewabout 5 years ago
Persevering for Patientsabout 5 years ago
Biopharma’s Reputation Gets a Well-Earned Shot in the Armabout 5 years ago
IP and Capitalabout 5 years ago
IP and COVID-19about 5 years ago
Pharma Steps Up for Public Health Inequitiesabout 5 years ago
FDA Relays Recent Achievements, Maps Plans for Progressabout 5 years ago
IP and CollaborationAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
5